Emicizumab in acquired haemophilia A: about two clinical cases and literature review
Acquired haemophilia A (AHA) is a rare and severe haemorrhagic autoimmune disease caused by autoantibodies directed against factor VIII (FVIII). Treatment is based on two principles, including haemostatic control to compensate FVIII inhibition and eradication of inhibiting antibodies using immunosup...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-08-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/20406207211038193 |